1. Home
  2. RNA
  3. RNA News

Latest Avidity Biosciences Inc. (RNA) News on November 8, 2025

RNA

MT Newswires

a day ago

Chardan Downgrades Avidity Biosciences to Neutral From Buy

Ovid Therapeutics (OVID) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
RNA

Zacks

4 days ago

Ovid Therapeutics (OVID) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Avidity Biosciences (RNA) Soars 42% on $12-Billion Novartis Merger
RNA

Insider Monkey

6 days ago

Avidity Biosciences (RNA) Soars 42% on $12-Billion Novartis Merger

Exploring Avidity Biosciences (RNA) Valuation Following Recent Share Price Surge
RNA

Simply Wall St.

6 days ago

Exploring Avidity Biosciences (RNA) Valuation Following Recent Share Price Surge

Here's Why Avidity Biosciences Stock Soared This Week (There's More to the Deal Than You Might Think)
RNA

Motley Fool

8 days ago

Here's Why Avidity Biosciences Stock Soared This Week (There's More to the Deal Than You Might Think)

Analysts Estimate Avidity Biosciences, Inc. (RNA) to Report a Decline in Earnings: What to Look Out for
RNA

Zacks

9 days ago

Analysts Estimate Avidity Biosciences, Inc. (RNA) to Report a Decline in Earnings: What to Look Out for

RNA

MT Newswires

10 days ago

Wolfe Research Downgrades Avidity Biosciences to Peer Perform From Outperform

RNA

MT Newswires

10 days ago

TD Cowen Downgrades Avidity Biosciences to Hold From Buy, Adjusts Price Target to $74 From $78

Novartis Lags Q3 Earnings, Announces $12B Avidity Biosciences Acquisition
RNA

Zacks

11 days ago

Novartis Lags Q3 Earnings, Announces $12B Avidity Biosciences Acquisition

Warner Bros. Discovery upgraded, F5 downgraded: Wall Street's top analyst calls
RNA

The Fly

11 days ago

Warner Bros. Discovery upgraded, F5 downgraded: Wall Street's top analyst calls

Avidity Biosciences (RNA) Moves 42.4% Higher: Will This Strength Last?
RNA

Zacks

11 days ago

Avidity Biosciences (RNA) Moves 42.4% Higher: Will This Strength Last?

Novartis Expects to Ride Out Patent Losses With Sales, Profit Growth Ahead
RNA

The Wall Street Journal

11 days ago

Novartis Expects to Ride Out Patent Losses With Sales, Profit Growth Ahead

RNA

MT Newswires

22 days ago

Avidity Biosciences Insider Sold Shares Worth $1,003,058, According to a Recent SEC Filing

Will FDA Feedback and Del-Zota BLA Timeline Shift Redefine Avidity Biosciences' (RNA) Late-Stage Pipeline?
RNA

Simply Wall St.

23 days ago

Will FDA Feedback and Del-Zota BLA Timeline Shift Redefine Avidity Biosciences' (RNA) Late-Stage Pipeline?

Avidity Biosciences (RNA) Gets 9% Boost from Higher PT, Rating
RNA

Insider Monkey

2 months ago

Avidity Biosciences (RNA) Gets 9% Boost from Higher PT, Rating

Avidity Biosciences (RNA) Is Down 11.2% After $600 Million Equity Raise to Fund Late-Stage Pipeline
RNA

Simply Wall St.

2 months ago

Avidity Biosciences (RNA) Is Down 11.2% After $600 Million Equity Raise to Fund Late-Stage Pipeline

RNA

MT Newswires

2 months ago

Avidity Biosciences Insider Sold Shares Worth $778,702, According to a Recent SEC Filing

RNA

MT Newswires

2 months ago

HC Wainwright Adjusts Avidity Biosciences Price Target to $87 From $68, Maintains Buy Rating

Takeda poaches top Lilly exec; Maze soars on early PKU drug data
RNA

BioPharma Dive

2 months ago

Takeda poaches top Lilly exec; Maze soars on early PKU drug data

RNA

MT Newswires

2 months ago

Avidity Biosciences Prices $600 Million Equity Offering

Avidity Biosciences Announces Pricing of Upsized Public Offering of Common Stock
RNA

PR Newswire

2 months ago

Avidity Biosciences Announces Pricing of Upsized Public Offering of Common Stock

RNA

MT Newswires

2 months ago

Top Midday Decliners

RNA

MT Newswires

4 months ago

Bernstein Initiates Avidity Biosciences at Outperform With $50 Price Target

RNA

MT Newswires

5 months ago

Wolfe Research Initiates Coverage on Avidity Biosciences With Outperform Rating, $55 Price Target

Avidity Biosciences, Inc. (RNA) Initiated with a Strong Buy at Raymond James
RNA

Insider Monkey

5 months ago

Avidity Biosciences, Inc. (RNA) Initiated with a Strong Buy at Raymond James

RNA

Investing.com

5 months ago

Raymond James bullish on biotech firms on favorable valuation

Avidity Biosciences to Present Topline Data from Phase 1/2 FORTITUDE™ Trial of Del-brax in People Living with Facioscapulohumeral Muscular Dystrophy at 32nd Annual FSHD Society International Research Congress
RNA

PR Newswire

5 months ago

Avidity Biosciences to Present Topline Data from Phase 1/2 FORTITUDE™ Trial of Del-brax in People Living with Facioscapulohumeral Muscular Dystrophy at 32nd Annual FSHD Society International Research Congress

Avidity Biosciences price target raised to $75 from $65 at Chardan
RNA

TipRanks

5 months ago

Avidity Biosciences price target raised to $75 from $65 at Chardan

Avidity Biosciences Touts Encouraging Functional Gains And Biomarker Reductions In Rare Muscular Weakness Disease Trial
RNA

Benzinga

5 months ago

Avidity Biosciences Touts Encouraging Functional Gains And Biomarker Reductions In Rare Muscular Weakness Disease Trial

Avidity Biosciences Announces Positive Topline Phase 1/2 FORTITUDE™ Data Demonstrating Consistent Improvement Across Multiple Functional Measures Compared to Placebo in Del-Brax Treated FSHD Participants
RNA

PR Newswire

5 months ago

Avidity Biosciences Announces Positive Topline Phase 1/2 FORTITUDE™ Data Demonstrating Consistent Improvement Across Multiple Functional Measures Compared to Placebo in Del-Brax Treated FSHD Participants

Avidity Biosciences Announces the Accelerated Approval Regulatory Pathway in the U.S. is Open for Del-Brax and Initiates the Global, Confirmatory Phase 3 FORWARD™ Study in FSHD
RNA

PR Newswire

5 months ago

Avidity Biosciences Announces the Accelerated Approval Regulatory Pathway in the U.S. is Open for Del-Brax and Initiates the Global, Confirmatory Phase 3 FORWARD™ Study in FSHD

This week in Trumponomics: Too bad TACO isn’t true
RNA

Yahoo Finance

5 months ago

This week in Trumponomics: Too bad TACO isn’t true

Starmer says Farage would spook the City and give us Truss 2 – he could be right
RNA

The Guardian

5 months ago

Starmer says Farage would spook the City and give us Truss 2 – he could be right

AI ecosystem isn't just Nvidia: Unlock it further with this ETF
RNA

Yahoo Finance Video

5 months ago

AI ecosystem isn't just Nvidia: Unlock it further with this ETF

Ford recalls more than 29,000 vehicles in the US, NHTSA says
RNA

Reuters

5 months ago

Ford recalls more than 29,000 vehicles in the US, NHTSA says

Smoke from Canadian wildfires worsens air quality in Dakotas, Midwestern states
RNA

USA TODAY

5 months ago

Smoke from Canadian wildfires worsens air quality in Dakotas, Midwestern states

Here's Why We Think HBT Financial (NASDAQ:HBT) Is Well Worth Watching
RNA

Simply Wall St.

5 months ago

Here's Why We Think HBT Financial (NASDAQ:HBT) Is Well Worth Watching

Saturday Sessions: OK Go performs "Love"
RNA

CBS News Videos

5 months ago

Saturday Sessions: OK Go performs "Love"

We're Not Very Worried About Black Swan Graphene's (CVE:SWAN) Cash Burn Rate
RNA

Simply Wall St.

5 months ago

We're Not Very Worried About Black Swan Graphene's (CVE:SWAN) Cash Burn Rate

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RNA

PR Newswire

6 months ago

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Avidity Biosciences First Quarter 2025 Earnings: Misses Expectations
RNA

Simply Wall St.

6 months ago

Avidity Biosciences First Quarter 2025 Earnings: Misses Expectations

Avidity Biosciences, Inc. (RNA) Reports Q1 Loss, Misses Revenue Estimates
RNA

Zacks

6 months ago

Avidity Biosciences, Inc. (RNA) Reports Q1 Loss, Misses Revenue Estimates

Avidity Biosciences Reports First Quarter 2025 Financial Results and Recent Highlights
RNA

PR Newswire

6 months ago

Avidity Biosciences Reports First Quarter 2025 Financial Results and Recent Highlights

Avidity Biosciences to Participate in Upcoming Investor Conference
RNA

PR Newswire

6 months ago

Avidity Biosciences to Participate in Upcoming Investor Conference

Trump’s FDA Sends a Bullish Signal to Biotech
RNA

The Wall Street Journal

7 months ago

Trump’s FDA Sends a Bullish Signal to Biotech

Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost
RNA

Investor's Business Daily

7 months ago

Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RNA

PR Newswire

7 months ago

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RNA

MT Newswires

7 months ago

Avidity Says Japan Grants Orphan Drug Status to Del-Desiran for Myotonic Dystrophy Type 1

Avidity Biosciences Receives Orphan Drug Designation in Japan for Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1
RNA

PR Newswire

7 months ago

Avidity Biosciences Receives Orphan Drug Designation in Japan for Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1

Avidity Biosciences (RNA): Among Unstoppable Stocks That Could Double Your Money
RNA

Insider Monkey

7 months ago

Avidity Biosciences (RNA): Among Unstoppable Stocks That Could Double Your Money

Avidity Biosciences (RNA) Soars 11.3%: Is Further Upside Left in the Stock?
RNA

Zacks

7 months ago

Avidity Biosciences (RNA) Soars 11.3%: Is Further Upside Left in the Stock?

Biotech stocks slide as Marks resignation seen being negative for sector
RNA

TipRanks

7 months ago

Biotech stocks slide as Marks resignation seen being negative for sector

Avidity Biosciences to Participate in Upcoming Investor Conference
RNA

PR Newswire

7 months ago

Avidity Biosciences to Participate in Upcoming Investor Conference

RNA

MT Newswires

7 months ago

Avidity Completes Enrollment in Del-brax Trial's Biomarker Group for Facioscapulohumeral Muscular Dystrophy

Avidity Biosciences Completes Enrollment in Biomarker Cohort in Phase 1/2 FORTITUDE™ Trial for Delpacibart Braxlosiran (del-brax) in People Living with Facioscapulohumeral Muscular Dystrophy
RNA

PR Newswire

7 months ago

Avidity Biosciences Completes Enrollment in Biomarker Cohort in Phase 1/2 FORTITUDE™ Trial for Delpacibart Braxlosiran (del-brax) in People Living with Facioscapulohumeral Muscular Dystrophy

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RNA

PR Newswire

8 months ago

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RNA

MT Newswires

8 months ago

Sector Update: Health Care Stocks Decline Premarket Monday

RNA

MT Newswires

8 months ago

Sector Update: Health Care

RNA

MT Newswires

8 months ago

Avidity Biosciences Reports Positive Topline Data From Phase 1/2 Trial of Del-Zota to Treat DMD

Avidity Biosciences Announces Positive Topline Del-zota Data Demonstrating Consistent, Statistically Significant Improvements in Dystrophin, Exon Skipping and Creatine Kinase in People Living with Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping in Phase 1/2 EXPLORE44® Trial
RNA

PR Newswire

8 months ago

Avidity Biosciences Announces Positive Topline Del-zota Data Demonstrating Consistent, Statistically Significant Improvements in Dystrophin, Exon Skipping and Creatine Kinase in People Living with Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping in Phase 1/2 EXPLORE44® Trial

RNA

MT Newswires

8 months ago

Citigroup Initiates Avidity Biosciences Inc at Buy With $70 Price Target

RNA

MT Newswires

8 months ago

Avidity Biosciences Insider Sold Shares Worth $602,614, According to a Recent SEC Filing

Avidity Biosciences Announces Upcoming Presentations at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
RNA

PR Newswire

8 months ago

Avidity Biosciences Announces Upcoming Presentations at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

RNA

MT Newswires

8 months ago

BMO Capital Initiates Avidity Biosciences at Outperform With $72 Price Target

Avidity Biosciences Full Year 2024 Earnings: Revenues Beat Expectations, EPS In Line
RNA

Simply Wall St.

8 months ago

Avidity Biosciences Full Year 2024 Earnings: Revenues Beat Expectations, EPS In Line

Avidity Biosciences Honors Rare Disease Day® and Global Efforts to Support People and Families Impacted by Rare Neuromuscular Diseases
RNA

PR Newswire

8 months ago

Avidity Biosciences Honors Rare Disease Day® and Global Efforts to Support People and Families Impacted by Rare Neuromuscular Diseases

RNA

MT Newswires

8 months ago

RBC Cuts Price Target on Avidity Biosciences to $61 From $67, Keeps Outperform, Speculative Risk

Avidity Biosciences, Inc. (RNA) Reports Q4 Loss, Tops Revenue Estimates
RNA

Zacks

8 months ago

Avidity Biosciences, Inc. (RNA) Reports Q4 Loss, Tops Revenue Estimates

Avidity Biosciences to Participate in Upcoming Investor Conferences
RNA

PR Newswire

8 months ago

Avidity Biosciences to Participate in Upcoming Investor Conferences

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RNA

PR Newswire

9 months ago

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

We're Hopeful That Avidity Biosciences (NASDAQ:RNA) Will Use Its Cash Wisely
RNA

Simply Wall St.

9 months ago

We're Hopeful That Avidity Biosciences (NASDAQ:RNA) Will Use Its Cash Wisely

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RNA

PR Newswire

10 months ago

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Avidity Biosciences, Inc. (RNA): The Biotech Stock with Biggest Upside Potential
RNA

Insider Monkey

10 months ago

Avidity Biosciences, Inc. (RNA): The Biotech Stock with Biggest Upside Potential

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RNA

PR Newswire

10 months ago

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RNA

MT Newswires

10 months ago

Avidity Biosciences Plans to Submit First Biologics License Application This Year

Avidity Biosciences Plans First BLA Submission and Accelerates Commercialization Preparations for Three Rare Muscle Disease Programs in 2025
RNA

PR Newswire

10 months ago

Avidity Biosciences Plans First BLA Submission and Accelerates Commercialization Preparations for Three Rare Muscle Disease Programs in 2025

Why Is Avidity Biosciences, Inc. (RNA) Among the Best Multibagger Stocks to Buy Right Now?
RNA

Insider Monkey

10 months ago

Why Is Avidity Biosciences, Inc. (RNA) Among the Best Multibagger Stocks to Buy Right Now?

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RNA

PR Newswire

a year ago

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RNA

MT Newswires

a year ago

HC Wainwright Initiates Coverage on Avidity Biosciences With Buy Rating, $72 Price Target

RNA

MT Newswires

a year ago

Avidity Biosciences Insider Sold Shares Worth $1,040,384, According to a Recent SEC Filing

RNA

MT Newswires

a year ago

Avidity Biosciences Insider Sold Shares Worth $831,605, According to a Recent SEC Filing

Avidity Biosciences to Participate in Upcoming Investor Conference
RNA

PR Newswire

a year ago

Avidity Biosciences to Participate in Upcoming Investor Conference

RNA

MT Newswires

a year ago

RBC Initiates Avidity Biosciences at Outperform, Speculative Risk With $67 Price Target

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RNA

PR Newswire

a year ago

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Biotech Stock Roundup: NVAX Q3 Results, SNDX Down on AML Data, RNA Surges on Study Data
RNA

Zacks

a year ago

Biotech Stock Roundup: NVAX Q3 Results, SNDX Down on AML Data, RNA Surges on Study Data

RNA Stock Hits Record High on Entering the Cardiac Disease Space
RNA

Zacks

a year ago

RNA Stock Hits Record High on Entering the Cardiac Disease Space

Avidity Bio Has Surged 416% This Year — And That's Before Today's 'Game-Changing' News
RNA

Investor's Business Daily

a year ago

Avidity Bio Has Surged 416% This Year — And That's Before Today's 'Game-Changing' News

Avidity Biosciences Announces New Precision Cardiology Development Candidates to Treat Rare Genetic Cardiomyopathies and Provides First Look at Next-Generation Technology Innovations
RNA

PR Newswire

a year ago

Avidity Biosciences Announces New Precision Cardiology Development Candidates to Treat Rare Genetic Cardiomyopathies and Provides First Look at Next-Generation Technology Innovations

Avidity Biosciences Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
RNA

Simply Wall St.

a year ago

Avidity Biosciences Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

Avidity Biosciences, Inc. (RNA) Reports Q3 Loss, Lags Revenue Estimates
RNA

Zacks

a year ago

Avidity Biosciences, Inc. (RNA) Reports Q3 Loss, Lags Revenue Estimates

Avidity Biosciences Reports Third Quarter 2024 Financial Results and Recent Highlights
RNA

PR Newswire

a year ago

Avidity Biosciences Reports Third Quarter 2024 Financial Results and Recent Highlights

Analysts Estimate Avidity Biosciences, Inc. (RNA) to Report a Decline in Earnings: What to Look Out for
RNA

Zacks

a year ago

Analysts Estimate Avidity Biosciences, Inc. (RNA) to Report a Decline in Earnings: What to Look Out for

An RNAi renaissance is creating a new generation of startups
RNA

BioPharma Dive

a year ago

An RNAi renaissance is creating a new generation of startups

Avidity Biosciences to Host Investor and Analyst Event Focused on Precision Cardiology Candidates and First Look at Next-Generation Technology Innovations on November 12, 2024
RNA

PR Newswire

a year ago

Avidity Biosciences to Host Investor and Analyst Event Focused on Precision Cardiology Candidates and First Look at Next-Generation Technology Innovations on November 12, 2024

Avidity Biosciences Pursues Potential Accelerated Approval Path with Initiation of Biomarker Cohort in FORTITUDE™ Trial for Delpacibart Braxlosiran (del-brax/AOC 1020) in People Living with Facioscapulohumeral Muscular Dystrophy
RNA

PR Newswire

a year ago

Avidity Biosciences Pursues Potential Accelerated Approval Path with Initiation of Biomarker Cohort in FORTITUDE™ Trial for Delpacibart Braxlosiran (del-brax/AOC 1020) in People Living with Facioscapulohumeral Muscular Dystrophy

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RNA

PR Newswire

a year ago

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Avidity Biosciences, Up 441%, Nears Another Record High As Dystrophy Space Heats Up
RNA

Investor's Business Daily

a year ago

Avidity Biosciences, Up 441%, Nears Another Record High As Dystrophy Space Heats Up

RNA

MT Newswires

a year ago

Avidity Biosciences Insider Sold Shares Worth $1,349,259, According to a Recent SEC Filing

Why Avidity Biosciences Zoomed to a 12% Gain This Week
RNA

Motley Fool

a year ago

Why Avidity Biosciences Zoomed to a 12% Gain This Week

FDA lifts clinical hold on Avidity’s lead antibody conjugate therapy trial
RNA

Pharmaceutical Technology

a year ago

FDA lifts clinical hold on Avidity’s lead antibody conjugate therapy trial

Share on Social Networks: